Iovance Biotherapeutics (IOVA) Tax Provisions (2023 - 2026)

Iovance Biotherapeutics (IOVA) has reported Tax Provisions for 4 consecutive years, with -$700000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Tax Provisions rose 61.92% year-over-year to -$700000.0; the TTM figure through Mar 2026 stood at -$81.3 million (down 2412.23% YoY), while the FY2025 annual figure was -$82.5 million, down 2847.89% from the prior year.
• Tax Provisions improved to -$700000.0 in Q1 2026 per IOVA's latest filing, from -$80.2 million in the prior quarter.
• Across five years, Tax Provisions topped out at $2.0 million in Q2 2025 and bottomed at -$80.2 million in Q4 2025.
• Historically, Tax Provisions has averaged -$7.5 million across 4 years, with a median of -$1.5 million in 2024.
• On a YoY basis, Tax Provisions climbed as much as 233.33% in 2025 and fell as far as 5115.06% in 2025.
• Iovance Biotherapeutics' Tax Provisions stood at -$1.8 million in 2023, then surged by 188.89% to $1.6 million in 2024, then plunged by 5115.06% to -$80.2 million in 2025, then jumped by 99.13% to -$700000.0 in 2026.
• Business Quant data shows IOVA's Tax Provisions at -$700000.0 in Q1 2026, -$80.2 million in Q4 2025, and -$2.4 million in Q3 2025.